Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A one-two punch of miR-126/126* against metastasis

Nature Cell Biology volume 15, pages 231–233 (2013)Cite this article

Subjects

MicroRNAs regulate cancer metastasis by modulating both the intrinsic properties of tumour cells and their interactions with the tumour stroma. Both strands of the miR-126/miR-126* duplex are now shown to simultaneously target the Sdf-1α cytokine to reduce the recruitment of mesenchymal stem cells and inflammatory monocytes to primary tumours, thereby inhibiting lung metastasis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Multiple roles of miR-126/126* in breast cancer metastasis.

References

  1. Garzon, R., Marcucci, G. & Croce, C. M. Nat. Rev. Drug Discov. 9, 775–789 (2010).

    Article  CAS  Google Scholar 

  2. Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S. & Calin, G. A. Nat. Rev. Cancer 9, 293–302 (2009).

    Article  CAS  Google Scholar 

  3. Zhang, Y. et al. Nat. Cell Biol. 15, 284–294 (2013).

    Article  CAS  Google Scholar 

  4. Parker, L. H. et al. Nature 428, 754–758 (2004).

    Article  CAS  Google Scholar 

  5. Fish, J. E. et al. Dev. Cell 15, 272–284 (2008).

    Article  CAS  Google Scholar 

  6. Wang, S. et al. Dev. Cell 15, 261–271 (2008).

    Article  Google Scholar 

  7. Meister, J. & Schmidt, M. H. Sci. World J. 10, 2090–2100 (2010).

    Article  CAS  Google Scholar 

  8. Watanabe, K. et al. Int. J. Cancer. 130, 2580–2590 (2012).

    Article  CAS  Google Scholar 

  9. Saito, Y. et al. Biochem. Biophys. Res. Commun. 379, 726–731 (2009).

    Article  CAS  Google Scholar 

  10. Tavazoie, S. F. et al. Nature 451, 147–152 (2008).

    Article  CAS  Google Scholar 

  11. Png, K. J., Halberg, N., Yoshida, M. & Tavazoie, S. F. Nature 481, 190–194 (2012).

    Article  CAS  Google Scholar 

  12. DeNardo, D. G. & Coussens, L. M. Breast Cancer Res. 9, 212 (2007).

    Article  Google Scholar 

  13. Karnoub, A. E. et al. Nature 449, 557–563 (2007).

    Article  CAS  Google Scholar 

  14. Lu, X. & Kang, Y. J. Biol. Chem. 284, 29087–29096 (2009).

    Article  CAS  Google Scholar 

  15. Ren, G. et al. Cell Stem Cell 11, 812–824 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guangwen Ren and Yibin Kang are in the Department of Molecular Biology, LTL255, Washington Road, Princeton University, Princeton, New Jersey 08544, USA,

    Guangwen Ren & Yibin Kang

Authors
  1. Guangwen Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yibin Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yibin Kang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ren, G., Kang, Y. A one-two punch of miR-126/126* against metastasis. Nat Cell Biol 15, 231–233 (2013). https://doi.org/10.1038/ncb2703

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncb2703

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer